RNAC

Cartesian Therapeutics Inc.

RNAC, USA

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

https://www.cartesiantherapeutics.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RNAC
stock
RNAC

683 Capital Management LLC Grows Stock Holdings in Cartesian Therapeutics, Inc. $RNAC Defense World

Read more →
RNAC
stock
RNAC

Independent Director of Cartesian Therapeutics Picks Up 168% More Stock simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$35.2857

Analyst Picks

Strong Buy

4

Buy

2

Hold

2

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-6.18

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

100.16 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.63 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-3,737.17 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 38.03% of the total shares of Cartesian Therapeutics Inc.

1.

FMR Inc

(8.9767%)

since

2025/06/30

2.

MPM Oncology Impact Management LP

(2.6383%)

since

2025/06/30

3.

Fidelity Select Biotechnology

(2.5604%)

since

2025/07/31

4.

BlackRock Inc

(2.5146%)

since

2025/06/30

5.

Siren, L.L.C.

(2.1663%)

since

2025/06/30

6.

Vanguard Group Inc

(1.909%)

since

2025/06/30

7.

Fidelity Growth Compy Commingled Pl S

(1.7803%)

since

2025/07/31

8.

HBM Healthcare Investments AG Ord

(1.5969%)

since

2025/06/30

9.

Fidelity Select Health Care

(1.4191%)

since

2025/07/31

10.

Fidelity Growth Company Fund

(1.3128%)

since

2025/07/31

11.

Vanguard Total Stock Mkt Idx Inv

(1.0837%)

since

2025/07/31

12.

Erste Asset Management GmbH

(1%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(0.922%)

since

2025/08/31

14.

Fidelity Advisor Health Care I

(0.8855%)

since

2025/07/31

15.

683 Capital Management LLC

(0.8422%)

since

2025/06/30

16.

Geode Capital Management, LLC

(0.842%)

since

2025/06/30

17.

State Street Corp

(0.7471%)

since

2025/06/30

18.

Citadel Advisors Llc

(0.4649%)

since

2025/06/30

19.

Fidelity Growth Company K6

(0.4162%)

since

2025/07/31

20.

Fidelity Small Cap Index

(0.3567%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.3534%)

since

2025/07/31

22.

Fidelity Series Growth Company

(0.342%)

since

2025/07/31

23.

Northern Trust Corp

(0.319%)

since

2025/06/30

24.

Marshall Wace Asset Management Ltd

(0.3178%)

since

2025/06/30

25.

iShares Russell 2000 Value ETF

(0.2714%)

since

2025/08/31

26.

Fidelity VIP Health Care Initial

(0.219%)

since

2025/07/31

27.

iShares Biotechnology ETF

(0.188%)

since

2025/08/31

28.

Fidelity Extended Market Index

(0.1768%)

since

2025/07/31

29.

Vanguard Russell 2000 ETF

(0.1707%)

since

2025/07/31

30.

GSA Capital Partners LLP

(0.16%)

since

2025/06/30

31.

Jacobs Levy Equity Management, Inc.

(0.1589%)

since

2025/06/30

32.

State St Russell Sm Cap® Indx SL Cl I

(0.122%)

since

2025/08/31

33.

Barclays PLC

(0.118%)

since

2025/06/30

34.

Morgan Stanley - Brokerage Accounts

(0.1123%)

since

2025/06/30

35.

Freestone Capital Holdings, LLC

(0.0997%)

since

2025/06/30

36.

Bank of New York Mellon Corp

(0.0961%)

since

2025/06/30

37.

Charles Schwab Investment Management Inc

(0.0958%)

since

2025/06/30

38.

Schwab Small Cap Index

(0.0957%)

since

2025/07/31

39.

Nuveen, LLC

(0.0942%)

since

2025/06/30

40.

NT R2000 Index Fund - NL

(0.0861%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.7308

EPS Estimate

-0.63

EPS Difference

-0.1008

Surprise Percent

-16%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.